Literature DB >> 20185576

Roles for aberrant CXCR3 signaling in basal cell carcinoma: a case for dual activity.

Yanlin Yu1, Glenn Merlino.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20185576      PMCID： PMC2861074          DOI： 10.2353/ajpath.2010.091284

Source DB:  PubMed          Journal:  Am J Pathol        ISSN： 0002-9440            Impact factor:   4.307


× No keyword cloud information.
  20 in total

1.  Activation of the transcription factor Gli1 and the Sonic hedgehog signalling pathway in skin tumours.

Authors:  N Dahmane; J Lee; P Robins; P Heller; A Ruiz i Altaba
Journal:  Nature       Date:  1997-10-23       Impact factor: 49.962

2.  Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer.

Authors:  Dipak Datta; Jesse A Flaxenburg; Sreenivas Laxmanan; Christopher Geehan; Martin Grimm; Ana Maria Waaga-Gasser; David M Briscoe; Soumitro Pal
Journal:  Cancer Res       Date:  2006-10-01       Impact factor: 12.701

3.  Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer.

Authors:  Tonya C Walser; Salah Rifat; Xinrong Ma; Namita Kundu; Chris Ward; Olga Goloubeva; Michael G Johnson; Julio C Medina; Tassie L Collins; Amy M Fulton
Journal:  Cancer Res       Date:  2006-08-01       Impact factor: 12.701

4.  Induction of basal cell carcinoma features in transgenic human skin expressing Sonic Hedgehog.

Authors:  H Fan; A E Oro; M P Scott; P A Khavari
Journal:  Nat Med       Date:  1997-07       Impact factor: 53.440

Review 5.  Chemokine receptor CXCR3: an unexpected enigma.

Authors:  Liping Liu; Melissa K Callahan; DeRen Huang; Richard M Ransohoff
Journal:  Curr Top Dev Biol       Date:  2005       Impact factor: 4.897

6.  Identification and partial characterization of a variant of human CXCR3 generated by posttranscriptional exon skipping.

Authors:  Jan Erik Ehlert; Christina A Addison; Marie D Burdick; Steven L Kunkel; Robert M Strieter
Journal:  J Immunol       Date:  2004-11-15       Impact factor: 5.422

7.  The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines.

Authors:  Lilach Goldberg-Bittman; Eran Neumark; Orit Sagi-Assif; Elina Azenshtein; Tsipi Meshel; Isaac P Witz; Adit Ben-Baruch
Journal:  Immunol Lett       Date:  2004-03-29       Impact factor: 3.685

8.  Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome.

Authors:  H Hahn; C Wicking; P G Zaphiropoulous; M R Gailani; S Shanley; A Chidambaram; I Vorechovsky; E Holmberg; A B Unden; S Gillies; K Negus; I Smyth; C Pressman; D J Leffell; B Gerrard; A M Goldstein; M Dean; R Toftgard; G Chenevix-Trench; B Wainwright; A E Bale
Journal:  Cell       Date:  1996-06-14       Impact factor: 41.582

9.  CXCR3 chemokine receptor-induced chemotaxis in human airway epithelial cells: role of p38 MAPK and PI3K signaling pathways.

Authors:  Syed Shahabuddin; Rong Ji; Ping Wang; Eugene Brailoiu; Na Dun; Yi Yang; Mark O Aksoy; Steven G Kelsen
Journal:  Am J Physiol Cell Physiol       Date:  2006-02-08       Impact factor: 4.249

10.  An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.

Authors:  Laura Lasagni; Michela Francalanci; Francesco Annunziato; Elena Lazzeri; Stefano Giannini; Lorenzo Cosmi; Costanza Sagrinati; Benedetta Mazzinghi; Claudio Orlando; Enrico Maggi; Fabio Marra; Sergio Romagnani; Mario Serio; Paola Romagnani
Journal:  J Exp Med       Date:  2003-06-02       Impact factor: 14.307
View more
  1 in total

Review 1.  Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12.

Authors:  Anup Kumar Singh; Rakesh Kumar Arya; Arun Kumar Trivedi; Sabyasachi Sanyal; Rathindranath Baral; Olivier Dormond; David M Briscoe; Dipak Datta
Journal:  Cytokine Growth Factor Rev       Date:  2012-09-16       Impact factor: 7.638
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.